UBS Group AG Boosts Position in MBX Biosciences, Inc. $MBX

UBS Group AG boosted its position in shares of MBX Biosciences, Inc. (NASDAQ:MBX) by 363.1% in the fourth quarter, Holdings Channel reports. The fund owned 281,212 shares of the company’s stock after purchasing an additional 220,487 shares during the quarter. UBS Group AG’s holdings in MBX Biosciences were worth $8,869,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of the company. Geode Capital Management LLC increased its position in MBX Biosciences by 27.0% in the second quarter. Geode Capital Management LLC now owns 348,447 shares of the company’s stock worth $3,976,000 after buying an additional 73,989 shares in the last quarter. Rhumbline Advisers increased its position in MBX Biosciences by 171.6% in the second quarter. Rhumbline Advisers now owns 23,662 shares of the company’s stock worth $270,000 after buying an additional 14,950 shares in the last quarter. XTX Topco Ltd purchased a new stake in MBX Biosciences in the second quarter worth about $135,000. The Manufacturers Life Insurance Company increased its position in MBX Biosciences by 73.8% in the second quarter. The Manufacturers Life Insurance Company now owns 87,097 shares of the company’s stock worth $994,000 after buying an additional 36,987 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in MBX Biosciences by 40.3% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,329 shares of the company’s stock worth $106,000 after buying an additional 2,682 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have commented on MBX shares. Weiss Ratings restated a “sell (d-)” rating on shares of MBX Biosciences in a research report on Tuesday, April 21st. Truist Financial upped their price target on MBX Biosciences from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. UBS Group restated a “buy” rating on shares of MBX Biosciences in a research report on Tuesday, February 24th. Barclays upped their price target on MBX Biosciences from $66.00 to $70.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Finally, Lifesci Capital upgraded MBX Biosciences to a “strong-buy” rating in a research report on Tuesday, March 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, MBX Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.22.

MBX Biosciences Price Performance

NASDAQ MBX opened at $32.45 on Monday. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -14.68 and a beta of 0.78. The business has a 50-day moving average price of $31.48 and a 200-day moving average price of $31.94. MBX Biosciences, Inc. has a twelve month low of $9.43 and a twelve month high of $45.85.

MBX Biosciences (NASDAQ:MBX) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.15. Research analysts expect that MBX Biosciences, Inc. will post -2.84 EPS for the current fiscal year.

Insider Buying and Selling at MBX Biosciences

In other MBX Biosciences news, CEO P. Kent Hawryluk acquired 18,500 shares of the company’s stock in a transaction dated Friday, March 13th. The stock was purchased at an average price of $28.41 per share, with a total value of $525,585.00. Following the completion of the purchase, the chief executive officer directly owned 486,777 shares in the company, valued at approximately $13,829,334.57. The trade was a 3.95% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

MBX Biosciences Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.